Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03113409
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Opioid Dependence Treatment Therapies in Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 55
- Registration Number
- NCT03098407
- Locations
- 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
The Effects of Opioid Taper on Opioid-Induced Hyperalgesia
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 15
- Registration Number
- NCT03063905
- Locations
- 🇺🇸
Avery Road Treatment Center, Rockville, Maryland, United States
🇺🇸Kolmac Clinic, Silver Spring, Maryland, United States
Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
- Conditions
- Interventions
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Braeburn Pharmaceuticals
- Target Recruit Count
- 1053
- Registration Number
- NCT02946073
- Locations
- 🇺🇸
Aventiv Research, Inc., Columbus, Ohio, United States
🇺🇸International Clinical Research Institute Inc., Overland Park, Kansas, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
- Conditions
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT02696434
- Locations
- 🇺🇸
John Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Neuroscience Research Institute, Inc., Winfield, Illinois, United States
🇺🇸Segal Institute for Clinical Research, Lauderhill, Florida, United States
Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 322
- Registration Number
- NCT02634788
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸Jean Brown Research, Salt Lake City, Utah, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
Project BEST: Buprenorphine Entry Into Substance Abuse Treatment
- Conditions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 209
- Registration Number
- NCT02583243
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Effects of Low Dose Buprenorphine on Recovery After Hip or Knee Arthroplasty
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Kuopio University Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT02575664
- Locations
- 🇫🇮
Kuopio University Hospital, Kuopio, Northern Savo, Finland
Improving Treatment Outcomes for Prescription Opioid Dependence
- Conditions
- Interventions
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 117
- Registration Number
- NCT02543944
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Buprenorphine Group Medical Visits in Primary Care
- Conditions
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT02526212
- Locations
- 🇺🇸
Comprehensive Health Care Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.